More than a third of pharmacists who participated in a survey said they have seen an increase in patients declining prescriptions due to the cost in the
last 12 months.
The survey was jointly conducted by the Pharmacists' Defence Association (PDA) and the Royal Pharmaceutical Society (RPS), extending their support for the
Prescription Charges Coalition (PCC).
Responding to the survey, 90 per cent of pharmacists admitted seeing cases where patients decline all the medicines on a prescription due to cost.
Nearly all respondents said they have seen cases where patients declined some of their prescribed medicines and more than a quarter of them have experienced
such situation often.
They have warned of the impact of prescription charges as patients are denying vital medicines, including those for blood pressure and mental health, inhalers,
antibiotics, pain relief, and statins, which can have potential consequences for the individual's health.
Extending its support for the Prescription Charges Coalition (PCC), the Pharmacists' Defence Association (PDA) is asking pharmacists in England to share their
experiences of patients denying prescriptions due to financial issues.
PDA members who have practiced in the country within the last 12 months are asked to complete the Prescription Charges Coalition survey by Sunday 28 January.
The PCC is an alliance of more than 50 organisations campaigning to abolish unfair prescription charges for people with long-term conditions in England.
All members of the coalition, including PDA and Royal Pharmaceutical Society (RPS), understand that if patients do not receive their prescribed medicines due to the
cost, their health may deteriorate, and this can increase costs for the National Health Service (NHS).
More than 500,000 women in England have benefitted from cheaper hormone replacement therapy (HRT) since the launch of the HRT prescription prepayment
certificates (PPC) on 1 April last year, according to the Department of Health and Social Care (DHSC).
HRT is the main treatment for negative menopause symptoms that can impact all areas of a woman's life.
Introduced as part of the government's Women's Health Strategy, which made menopause a priority area, the HRT PPC reduced prescription costs to just £19.30 per
year, helping patients save hundreds of pounds in prescription charges.
The DHSC has confirmed that more than £11 million was saved by women using the PPC in the last nine months.
Using the HRT PPC, patients can get a range of HRT items, including patches, tablets, and topical preparations at reduced prices, and they can use it many times
as needed throughout the year.
The Royal Pharmaceutical Society (RPS) has welcomed the Health Secretary Sajid Javid's plan to appoint Hormone Replacement Therapy (HRT) tsar to tackle the medicine shortages.
On Sunday (April 24) Sajid Javid told the Mail that he planned to tackle the problem (shortage of HRT medicine) by appointing a new HRT tsar with the role modelled on that of Kate Bingham, who successfully led the government's Covid vaccine taskforce.
"The difficulties in accessing HRT medicine have unfairly impacted women's mental health," said RPS President, Professor Claire Anderson.
"I look forward to working with this new champion for HRT and the Government on how we can better support women's health, building on the positive move to reduce
prescription charges for HRT for women."
Anderson also stressed that "the Government should now go further and end unfair prescription charges for patients in England altogether."